Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial

dc.contributor.authorHerrero Cortina, Beatriz
dc.contributor.authorAlcaraz, Victoria
dc.contributor.authorVilaró, Jordi
dc.contributor.authorTorres Martí, Antoni
dc.contributor.authorPolverino, Eva
dc.date.accessioned2019-12-02T15:29:13Z
dc.date.available2019-12-02T15:29:13Z
dc.date.issued2018-09-26
dc.date.updated2019-12-02T15:29:13Z
dc.description.abstractBackground: The role of hyaluronic acid plus hypertonic saline (HA+HS) as a mucoactive treatment in patients with bronchiectasis is still unknown. This study evaluated whether HA+HS solution enhances similar sputum quantity with better safety profile than HS alone in patients with bronchiectasis. Methods: In this double-blind randomized crossover trial, three solutions (7% HS; 0.1% HA +7%HS; and 0.9% isotonic saline, IS) were compared in outpatients with bronchiectasis and chronic sputum expectoration. Participants inhaled each solution across four consecutive sessions. All sessions, except on session 3, also included 30 minutes of airway clearance technique. A 7-day washout period was applied. Sputum weight was collected during the sessions (primary outcome) as well as during a 24-hour follow-up. The Leicester Cough Questionnaire (LCQ) and lung function were measured before/after each treatment arm. Safety was assessed by the monitoring of adverse events (AEs). Results: Twenty-eight patients with bronchiectasis (mean age of 64.0 (17.9) and FEV1% 60.9 (24.6) of predicted) were recruited. HS and HA+HS promoted similar expectoration during sessions, both being greater than IS [median difference HS vs. IS 3.7 g (95% CI 0.5-6.9); HA+HS vs. IS 3.2 g (95%CI 0.5-5.9)]. Sputum expectorated exclusively during the ACT period was similar across all treatment arms [HS vs. IS −0.3 g (95% CI −1.7 to 0.9); HA+HS vs. IS 0.0 g (95% CI −1.3 to 1.4); HS vs. HA+HS 0.0 g (95% CI −1.2 to 0.4)]. Sputum collected over the 24-hour follow-up tended to be lower for HS and HA+HS compared with IS [HS vs. IS −1.7 g (95% CI −4.2 to 0.0); HA+HS vs. IS −1.1 g (95%CI −3.6 to 0.7)]. No differences in LCQ or lung function were observed. Most severe AEs were reported using HS. Conclusion: HS and HA+HS were more effective on sputum expectoration than IS in patients with bronchiectasis, reporting HA+HS better safety profile than HS.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec686152
dc.identifier.issn1941-2711
dc.identifier.pmid29878856
dc.identifier.urihttps://hdl.handle.net/2445/145863
dc.language.isoeng
dc.publisherMary Ann Liebert
dc.relation.isformatofReproducciót del document publicat a: https://doi.org/10.1089/jamp.2017.1443
dc.relation.ispartofJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, vol. 31, num. 5, p. 281-289
dc.relation.urihttps://doi.org/10.1089/jamp.2017.1443
dc.rightscc by (c) Herrero Cortina, et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationInfeccions respiratòries
dc.subject.classificationMalalties pulmonars obstructives cròniques
dc.subject.classificationEsput
dc.subject.otherRespiratory infections
dc.subject.otherChronic obstructive pulmonary diseases
dc.subject.otherSputum
dc.titleImpact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
686152.pdf
Mida:
240.22 KB
Format:
Adobe Portable Document Format